| SUPERNUS PHARMAC.DL -,001 |
| USA |
| Gesundheit |
| US8684591089 / A1JX3U |
| S49 (Frankfurt) / SUPN (NASDAQ) |
| FRA:S49, ETR:S49, S49:GR, NASDAQ:SUPN |
| - |
| https://www.supernus.com/ |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its primary function is to innovate therapeutic solutions that address..
>Volltext.. |
| 2297.02 Mio. EUR |
| 1999.85 Mio. EUR |
| 674.07 Mio. EUR |
| 43.12 Mio. EUR |
| -25.18 Mio. EUR |
| -0.44 EUR |
| 35.49 Mio. EUR |
| 160.41 Mio. EUR |
| 72.24 Mio. EUR |
| 1.03 |
| 8.89% |
| -143.88% |
| - |
| - |
| - |
| - |
| SUPERNUS |
| 03.08.26 |
|
||||
|